Developing Better Ways to Judge Liver Scarring Reversal in Fatty Liver Disease
Studies liver biopsies and health records of adults with fatty liver disease and scarring.
Plain-language title generated from the registry record
Registry title: Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with NASH (fatty liver with inflammation) and liver scarring at stage F2-4, confirmed by liver biopsy.
- Age
- 18 to 70 years at the time of the liver biopsy.
- Sex
- Anyone can join, men and women.
- Disease stage
- NASH with liver scarring (fibrosis) at stage F2-4, confirmed by liver biopsy.
Main reasons for not taking part
- Other liver diseases, such as HCV infection, HIV infection, alcoholic, autoimmune or drug-induced liver disease
- Pregnancy
- Liver cancer or possible liver cancer before the biopsy
- Decompensated cirrhosis (for example ascites or bleeding)
- Other cancers, or a liver transplant
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06707129, who can take part
Where in China
- Beijing Ditan Hospital, Capital Medical UniversityBeijing, ChinaContact: Minghui Li, DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Municipal Administration of Hospitals
- Trial code
- NCT06707129
- Record updated
- 27 November 2024
- Original description
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.Read full original descriptionShow less
Establishment of Precise Histological Evaluation Criteria for Reversal of NASH Fibrosis
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.
Inclusion: Aged between 18 and 70 years at the time of liver biopsy; Gender is not limited; Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4; Signed written informed consent.
Exclusion: Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases; There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation; Women during pregnancy; Patients considered by the investigator to be unsuitable for this study.